Cancer Clinical Investigators Should Converge with Pharmacometricians

被引：3
|
作者：
Maitland, Michael L. [1 ,2 ]
O'Cearbhaill, Roisin E. [3 ,4 ]
Gobburu, Jogarao [5 ]
机构：
[1] Inova Schar Canc Inst, 3289 Woodburn Rd, Annandale, VA 22003 USA
[2] Univ Virginia, Annandale, VA USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Univ Maryland, Sch Pharm, Ctr Translat Med, Baltimore, MD 21201 USA
来源：
CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 17期
关键词：
D O I：
10.1158/1078-0432.CCR-19-1067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The applied quantitative science pharmacometrics has significantly enhanced cancer therapeutics development. Pharmacometrics is now improving our understanding of complex diagnostics. Through the concept of convergence and methods of quantitative and systems pharmacology, pharmacometrics is poised to interconnect mathematical models of disease and therapy to advance cancer care.
引用
收藏
页码：5182 / 5184
页数：3
相关论文
共 50 条
12345